鲁他卡因通过向糖尿病病中的CK2α来缓解炎症和纤维化
Juan Chen1, Zi-Yun Hu1, Yu Ma1
1Department of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, PR China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|October 1, 2024
概括
鲁他卡 (Rut) 通过减少损伤和炎症来保护糖尿病病 (DN). 它向蛋白激酶CK2α (CK2α),抑制导致脏中细胞外基质积累的途径.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 糖尿病病 (DN) 是糖尿病的一种严重并发症,其特征是质介质细胞 (GMC) 增殖和细胞外基质 (ECM) 沉积,导致质硬化.
- Rutaecarpine (Rut),一种来自Fructus Evodiae的类化合物,具有各种生物活性,但其在DN中的作用尚不清楚.
研究的目的:
- 为了研究Rutaecarpine (Rut) 对糖尿病脏病 (DN) 中的质介质细胞 (GMC) 的保护作用.
- 阐明Rut在DN中的作用的潜在机制,包括其对ECM产生,炎症和特定信号通路的影响.
主要方法:
- 使用db/db小鼠和高葡萄糖 (HG) 治疗的小鼠中细胞 (SV40 MES-13) 来建模DN.
- 评估Rut对尿路白蛋白,功能和病理的影响.
- 研究了Rut对ECM产生,炎症,TGF-β1/Smad3和NF-κB信号传递的影响.
- 通过计算预测,分子对接和实验分析 (CETSA,SPR) 将蛋白质激酶CK2α (CK2α) 确定为Rut的分子标.
- 在接受HG治疗的细胞中,研究了CK2α基因沉默后Rut的疗效.
主要成果:
- 治疗减轻了尿路白蛋白,改善了功能,并在体内减少了病理损伤.
- 鲁特显著降低了ECM的产生和脏炎症.
- 鲁特抑制了TGF-β1 / Smad3和NF-κB信号通路的激活,无论是体外还是体外.
- 蛋白激酶CK2α (CK2α) 已被证实是Rut的直接目标.
- 在CK2α沉默后,Rut的保护作用在HG处理的细胞中被废除了.
结论:
- 这项研究表明,路泰卡尔 (Rut) 对糖尿病病 (DN) 有保护作用.
- 鲁特通过向CK2α和抑制TGF-β1/Smad3和NF-κB信号通路来抑制ECM的产生和炎症.
- 鲁特显示出作为治疗糖尿病病的新型治疗剂的潜力.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
510
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
122
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
2
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
2
01:25Antihypertensive Drugs: Direct Renin Inhibitors
506
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
506
01:25cAMP-dependent Protein Kinase Pathways
6.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.2K
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K